


# PRODUCT INFORMATION



**PF-03882845**

Item No. 10669

**CAS Registry No.:** 1023650-66-9  
**Formal Name:** 2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3S,3aR,4,5-tetrahydro-2H-benz[g]indazole-7-carboxylic acid  
**MF:** C<sub>24</sub>H<sub>22</sub>ClN<sub>3</sub>O<sub>2</sub>  
**FW:** 419.9  
**Purity:** ≥98%  
**Supplied as:** A solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

## Laboratory Procedures

PF-03882845 is supplied as a solid. A stock solution may be made by dissolving the PF-03882845 in the solvent of choice, which should be purged with an inert gas. PF-03882845 is sparingly soluble (1-10 mg/ml) in DMSO.

## Description

PF-03882845 is a non-steroidal mineralocorticoid receptor antagonist (IC<sub>50</sub> = 26 nM).<sup>1</sup> It is selective for the mineralocorticoid receptor over the androgen, glucocorticoid, and progesterone receptors in reporter assays using Huh7 cells (IC<sub>50</sub>s = >10,000, >10,000, and 1,880 nM, respectively). PF-03882845 (40 and 100 mg/kg) prevents blood pressure increases and kidney damage in rats fed a high-salt diet. It inhibits severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) guanine-N7 methyltransferase in a homogenous time-resolved fluorescence (HTRF) assay (IC<sub>50</sub> = 1.1 μM) and reduces SARS-CoV-2 infectivity in Vero E6 cells (EC<sub>50</sub> = 10.97 μM).<sup>2</sup> PF-03882845 also inhibits Zika virus NS2B-NS3 protease in a reporter assay (IC<sub>50</sub> = 1 μM) and reduces Zika virus infectivity in neural stem cells generated from human induced pluripotent stem cells (iPSCs; IC<sub>50</sub> = 10.8 μM).<sup>3</sup>

## References

1. Meyers, M.J., Arhancet, G.B., Hockerman, S.L., *et al.* Discovery of (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benz[g]indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathy. *J. Med. Chem.* **53**(16), 5979-6002 (2010).
2. Basu, S., Mak, T., Ulferts, R., *et al.* Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of Nsp14 RNA cap methyltransferase. *Biochem. J.* **478**(13), 2481-2497 (2021).
3. Abrams, R.P.M., Yasgar, A., Teramoto, T., *et al.* Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. *Proc. Natl. Acad. Sci. USA* **117**(49), 31365-31375 (2020).

### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 04/13/2026

## CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM